Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks

EyePoint, Inc. (NASDAQ:EYPT) is among the best get rich quick stocks to buy right now. Andreas Argyrides, an analyst at Chardan, significantly lifted the price target on EyePoint, Inc. (NASDAQ:EYPT) to $65 from $29 on July 1. Calling the company “a de-risked, single-asset, catalyst-rich story,” the firm maintained a Buy rating on the shares following a transfer of coverage.

The firm expects readouts from Phase 3 studies of DURAVYU in wet AMD, scheduled for August and October 2026, to be the key catalysts. The two biggest retinal markets, wet AMD and DME, are anticipated to achieve $13 billion in U.S. sales next year, the firm said.

science, laboratory, bioscience

Phovoir/Shutterstock.com

In one year, EyePoint, Inc. (NASDAQ:EYPT) has returned twice as much as the market, with nearly 25% outperformance. Overall, the company has a Buy rating from all twelve analysts covering the stock. With an upside potential of 153.93% based on the one-year median price target of $35.50, EYPT is among the best get rich quick stocks to buy right now.

EyePoint, Inc. (NASDAQ:EYPT) is a Massachusetts-based company specializing in therapeutics for people living with serious retinal diseases. The company’s pipeline is built on its proprietary bioerodible Durasert E technology.

While we acknowledge the risk and potential of EYPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EYPT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1